Bret Jensen is one of 25 Seeking Alpha Contributors participating in the 2017 DIY Investing Summit. In the summit, two of the questions I asked Bret what his "State of the Markets" address to DIY investor would be and how is he positioning himself for 2017. Below is an excerpt from the interview and a summary of his response. Bret's "State of the Markets" and positioning for 2017... Expects 2017 to be a lot like 2016 with lots of unknowns in the world. China and the new administration are both bit question marks. Biotech and Pharma gains are sustainable as they exit a bear market. The market is fairly to slightly overvalued, domestic small caps should do well. Infrastructure and yield stocks are overvalued. More... This is just a small excerpt of what's covered in the interview. The interview is full of detailed tips on Bret's core investment strategies, top advice for DIY investors, and specific ways he's positioning for 2017. Enjoy the full interview with Bret and other top investors on Seeking Alpha. Registration for the summit is now open and free for a limited time. Don't like audio/video interviews? If you prefer to read content as opposed to watch and listen, detailed summary sheets have been created for every interview as an optional add-on. Full list of summit contributors: Chris DeMuth, Bret Jensen, Rida Morwa, Brad Thomas, Eric Parnell, Ian Bezek, Richard Lejeune, Richard Berger, Aurelien Windenberger, Doug Eberhardt, Dividend Sensei, Ralph Baker, Lawrence Fuller, Double Dividend Stocks, Mark Bern, Mark Hibben, Dividend House, J Mintzmyer, William Koldus, Damon Verial, Avi Gilburt, Shailesh Kumar, Chuck Carnevale, Adam Aloisi, and Colorado Wealth Management Join Bret at the DIY Investor Summit (free for a limited time) where he shares detailed tips on his core investment strategies, top advice for DIY investors, and specific ways he's positioning for 2017. Companies mentioned in Bret's interview: Amicus Therapeutics (FOLD), Ocular Therapeutix (OCUL), Adamas Pharmaceuticals (ADMS), ACADIA Pharmaceuticals (ACAD), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Cara Therapeutics (CARA), Aerie Pharmaceuticals (AERI), Health Insurance Innovations (HIIQ), Biotechnology (IBB), and S&P 500 (SPY) Additional Disclosure: This article is for information purposes only. There are risks involved with investing including loss of principal. Brian and Investor in the Family make no explicit or implicit guarantee with respect to performance or the outcome of any investment or projections made. There is no guarantee that the goals of the strategies discussed by Brian and Investor in the Family will be met.